Date, time: November 10th 2020, 14:00-16:30 CEST
Recording: https://www.youtube.com/watch?v=dC4h51aGEAY
NB. the recording is only from part 1 of the program adressed below.
Precision Medicine: A Health Economics Perspective
Learn about the challenges in precision medicine from the perspective of health economics, discuss the landscape of precision medicine and how current guidelines and regulations needs to be updated and adjusted. Link to the recording is available below!
Stakeholders include health economists, researchers, clinicians, industry and public organizations
Background. Reimbursement of pharmaceuticals is based on cost-effectiveness analysis. These analyses synthesize information from multiple sources, where the efficacy typically is based on information from randomized controlled trials.
The introduction of precision medicine implies several challenges for the recommended framework:
- Measuring efficacy when randomized controlled trial is not possible
- Accounting for uncertainty, when samples sizes are very small
- Development of financial incentives and optimal reimbursement systems, for instance considering adaptive partial approval process
The program is adressed below:
Part 1: English
14.00 - 14.05: Welcome
- Introduction and program
Eline Aas, University of Oslo - The BigMed-project
Vibeke Binz Vallevik, BigMed and DNV GL
14.05 - 15.00: Keynote
- Economic Evaluation and Personalized Medicine (HEcoPerMed)
Apostolos Tsiachristas, Ass. prof., University of Oxford and HEcoPerMed
15.00 - 15.50: Pitching research
- Framework for precision medicine
Lars Asphaug, Oslo Economics - Precision and uncertainty in the evaluation of
diagnostic algorithms in Non-Alcoholic Fatty Liver Disease
Lina Gruneau, PhD student, Department of Health, Medicine and Caring Science, Linköping University, PRECISE - Quantifying the consequences of immature trial
evidence for informing coverage decisions
Mathyn Vervaart, PhD student, Department of Health Management and Health Economics, University of Oslo and Norwegian Medicines Agency, PRECISE - Cost-Effectiveness analysis of Precision
Medicine: The MetAction study
Monica Gomez, Research assistant, Department of Health Management and Health Economics, University of Oslo and BigMed - Planning for the future – INSIGHT
Eline Aas at Department of Health Management and Health Economics, University of Oslo
Part 2: Norwegian
15.50 - 16.30: Paneldebatt
- Utfordringer med hensyn til godkjenning og implementering av presisjonsmedisin
- Ordstyrer: Ivar Sønbø Kristiansen, Oslo Economics og Professor Emeritus UiO
- Paneldeltakere: Bjørn Oddvar Strøm, Statens Legemiddelverk, Grethe Foss fra Helsedirektoratet og Petter Foss fra legemiddelfirmaet Novartis, og medlem i LMIs helseøkonomiske utvalg
Access the recording of part 1 via the link published at the top of this page!
Please, reach out to the contacts listed below if you have any further questions.
Relevant Projects
Big data management for the precise treatment of three patient groups
Learn about the challenges in precision medicine from the perspective of health economics, discuss the landscape of precision medicine and how current guidelines and regulations needs to be updated and adjusted. Link to the recording is available here!